Table 3.

Baseline and ongoing data collection

Screening visit	• Age, sex, target weight, duration on dialysis, cause of end-stage kidney disease, vascular access type
	• Serum calcium, phosphate, parathyroid hormone, Kt/V, 25-hydroxy vitamin D, 1,25-dihydroxy vitamin D
	• Medication use
	• GODIN leisure-time activity questionnaire
	• DASI aerobic capacity questionnaire
Baseline study visit	• Serum calcium, phosphate, parathyroid hormone, Kt/V, 25OHD level, 1,25-dihydroxy vitamin D level, catecholamines
	• Renin, aldosterone, angiotensin II
	• Delivered dose of dialysis (Kt/V)
	• Power spectral analysis (LF, HF, LF:HF) and time domain (SDNN, SDANN, pNN50%) HRV parameters
Study visits every 6 weeks up to 24 weeks	• Serum calcium, serum phosphate, parathyroid hormone, 25OHD, 1,25-dihydroxy-vitamin D, catecholamines
	• Renin, aldosterone, angiotensin II
	• Delivered dose of dialysis (Kt/V)
	• Power spectral analysis (LF, HF, LF:HF) and time domain (SDNN, SDANN, pNN50%) HRV parameters